Inflexion to acquire Pharmaspectra

The firm will be drawing equity from its Inflexion Enterprise Fund IV, which closed on £250m in 2016. The fund invests equity of £10-20m for both majority and minority stakes in UK-based lower-mid-market companies.

Unquote understands Inflexion was not involved in an auction for the company, which was sourced as a proprietary transaction. No debt was used in the transaction.

The company will continue to invest in its technology and sales and marketing functions following the investment.

Company
Founded in 2005 and headquartered in London, Pharmaspectra provides scientific dissemination data and analytics software to the pharmaceutical and biotechnology industries. It operates offices in the UK, the US and Switzerland and a data processing centre in Chennai. It employs 115 staff.

People
Inflexion Private Equity – Ben Long (partner); Saloshnee Nightingale (investment executive).
Pharmaspectra – Jez Moulding (CEO).

Advisers
Equity – Results International (corporate finance); BDO (financial de diligence).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• UK / Ireland
• Support services
• Inflexion Private Equity
• BDO LLP
• United Kingdom
• healthcare